Literature DB >> 18066592

C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma.

Rosario S Rivera1, Hitoshi Nagatsuka, Mehmet Gunduz, Beyhan Cengiz, Esra Gunduz, Chong Huat Siar, Hidetsugu Tsujigiwa, Ryo Tamamura, Kok Ng Han, Noriyuki Nagai.   

Abstract

C-kit is a trans-membrane receptor tyrosine kinase (RTK) encoded by the proto-oncogene KIT located at 4q11-12. Gain-of-function mutations arising to c-kit activation independent of its ligand were observed in various tumors related to germ cells, mast cells, and interstitial cells of Cajal. C-kit also participates in melanocyte development; hence, its involvement in oral mucosal melanoma (OMM) tumorigenesis was investigated. Immunohistochemistry and mutation analysis were performed using 18 cases of human primary OMM. Results revealed 16 cases positive to c-kit protein. Atypical melanocytes expressed c-kit. All in situ components expressed c-kit, but only four cases exhibited intense expression in the invasive component. Missense mutations were observed in four cases, and two of those correlated with increased protein expression. C-kit expression in atypical melanocytes suggests the role of c-kit in the early stage of OMM tumorigenesis. C-kit protein expression correlated with activating mutations indicating the pertinent role of the proto-oncogene KIT in the tumorigenesis of OMM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18066592     DOI: 10.1007/s00428-007-0524-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  40 in total

1.  Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.

Authors:  K T Montone; P van Belle; R Elenitsas; D E Elder
Journal:  Mod Pathol       Date:  1997-09       Impact factor: 7.842

2.  Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients.

Authors:  Dae Young Kang; Cheol Keun Park; Jong Sang Choi; So Young Jin; Hyun Jung Kim; Mee Joo; Mi Seon Kang; Woo Sung Moon; Ki Jung Yun; Eun Sil Yu; Haeyun Kang; Kyoung-Mee Kim
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

3.  Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.

Authors:  G Fiorentini; S Rossi; G Lanzanova; M Biancalani; A Palomba; P Bernardeschi; P Dentico; U De Giorgi
Journal:  J Exp Clin Cancer Res       Date:  2003-12

4.  An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients.

Authors:  John B Alexis; Antonio E Martinez; Jose Lutzky
Journal:  Melanoma Res       Date:  2005-08       Impact factor: 3.599

5.  c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi.

Authors:  A Ohashi; Y Funasaka; M Ueda; M Ichihashi
Journal:  Melanoma Res       Date:  1996-02       Impact factor: 3.599

6.  Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis.

Authors:  Carlynn Willmore; Joseph A Holden; Luming Zhou; Sheryl Tripp; Carl T Wittwer; Lester J Layfield
Journal:  Am J Clin Pathol       Date:  2004-08       Impact factor: 2.493

7.  Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.

Authors:  Gaëlle Lefevre; Anne-Lise Glotin; Armelle Calipel; Frédéric Mouriaux; Thi Tran; Zoulika Kherrouche; Claude-Alain Maurage; Christian Auclair; Frédéric Mascarelli
Journal:  J Biol Chem       Date:  2004-05-15       Impact factor: 5.157

8.  Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array.

Authors:  Steven S Shen; Peter S Zhang; Omar Eton; Victor G Prieto
Journal:  J Cutan Pathol       Date:  2003-10       Impact factor: 1.587

9.  The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.

Authors:  Julie Litz; G Sakuntala Warshamana-Greene; Geoffrey Sulanke; Kenneth E Lipson; Geoffrey W Krystal
Journal:  Lung Cancer       Date:  2004-12       Impact factor: 5.705

10.  Lack of clinical efficacy of imatinib in metastatic melanoma.

Authors:  S Ugurel; R Hildenbrand; A Zimpfer; P La Rosée; P Paschka; A Sucker; P Keikavoussi; J C Becker; W Rittgen; A Hochhaus; D Schadendorf
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

View more
  43 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

Review 3.  Mucosal melanoma: pathogenesis, clinical behavior, and management.

Authors:  Michael A Postow; Omid Hamid; Richard D Carvajal
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

Review 4.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

5.  Primary Gingival Melanoma: An Important Entity.

Authors:  Wala Ben Kridis; Jihène Feki; Lobna Ayedi; Afef Khanfir; Nabil Toumi; Mohamed Abdelmoula; Tahia Boudawra; Jamel Daoud; Mounir Frikha
Journal:  J Maxillofac Oral Surg       Date:  2015-07-24

6.  Expression of Sox10 and c-kit in sinonasal mucosal melanomas arising in the Chinese population.

Authors:  Hong Gang Liu; Max Xiangtian Kong; Qian Yao; Shu Yi Wang; Robert Shibata; Herman Yee; Frank Martiniuk; Beverly Y Wang
Journal:  Head Neck Pathol       Date:  2012-06-27

7.  KGF Promotes Paracrine Activation of the SCF/c-KIT Axis from Human Keratinocytes to Melanoma Cells.

Authors:  Francesca Belleudi; Giorgia Cardinali; Daniela Kovacs; Mauro Picardo; Maria Rosaria Torrisi
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

8.  Melanoma: Molecular Pathogenesis and Therapeutic Management.

Authors:  Yuxin Liu; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2014

9.  Ipilimumab for patients with advanced mucosal melanoma.

Authors:  Michael A Postow; Jason J Luke; Mark J Bluth; Nikhil Ramaiya; Katherine S Panageas; Donald P Lawrence; Nageatte Ibrahim; Keith T Flaherty; Ryan J Sullivan; Patrick A Ott; Margaret K Callahan; James J Harding; Sandra P D'Angelo; Mark A Dickson; Gary K Schwartz; Paul B Chapman; Sacha Gnjatic; Jedd D Wolchok; F Stephen Hodi; Richard D Carvajal
Journal:  Oncologist       Date:  2013-05-28

10.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.

Authors:  Carlos A Torres-Cabala; Wei-Lien Wang; Jonathan Trent; Dan Yang; Su Chen; John Galbincea; Kevin B Kim; Scott Woodman; Michael Davies; Jose A Plaza; J W Nash; Victor G Prieto; Alexander J Lazar; Doina Ivan
Journal:  Mod Pathol       Date:  2009-08-28       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.